Exclusive Summary

• Targets the world's most common cancer (specifically the HR+/HER2- subtype accounting for 70% of breast cancer cases) and is the ONLY CDK4/6 inhibitor approved for early-stage adjuvant therapy, ensuring a massive patient base.
• Scheduled for US FDA filing in 2026, offering FDA-level cGMP quality endorsement and a complete range of dosage strengths (50/100/150/200mg) perfectly suited for expedited global registrations.
• Strategically timed to hit the 2027-2029 global patent cliff, ranking in the first tier of generic development to help partners secure first-to-market or early-market entry opportunities.
• Provides overwhelming cost advantages compared to the >$14,000/month originator, making it highly competitive for national tenders and out-of-pocket markets via distribution partnerships.